Lymphoma Characterization in MSH2−/− Mice
Mouse . | Histology . | Immunophenotype . | TdT . | TCR Status β/δ . | RBTN-2 . | Tal-1 . |
---|---|---|---|---|---|---|
D8 | Lymphoblastic | B220−, CD3+, CD4−, CD8− | +ve | +/+ | +ve | +ve |
L12 | Lymphoblastic | B220−, CD3+, CD4−, CD8− | +ve | +/+ | +ve | +ve |
R15 | Lymphoblastic | B220−, CD3+, CD4−, CD8− | +ve | +/+ | +ve | −ve |
H27 | Lymphoblastic | B220−, CD3+, CD4−, CD8− | +ve | −/+ | +ve | −ve |
K7 | Lymphoblastic | B220−, CD3+, CD4−, CD8− | +ve | −/+ | +ve | −ve |
P21 | Lymphoblastic | B220−, CD3+, CD4+, CD8+ | +ve | +/+ | +ve | +ve |
T9 | Lymphoblastic | B220−, CD3+, CD4+, CD8+ | +ve | +/+ | +ve | +ve |
L15 | Lymphoblastic | B220−, CD3+, CD4+, CD8+ | +ve | +/+ | +ve | −ve |
F3 | Lymphoblastic | B220−, CD3+, CD4+, CD8+ | +ve | +/+ | +ve | −ve |
B20 | Lymphoblastic | B220−, CD3+, CD4+, CD8+ | +ve | +/+ | +ve | −ve |
S7 | Lymphoblastic | B220−, CD3+, CD4+, CD8+ | +ve | −/+ | +ve | −ve |
C31 | Lymphoblastic | B220−, CD3+, CD4+, CD8+ | +ve | −/+ | +ve | +ve |
F1-C2 | Lymphoblastic | B220−, CD3+, CD4+, CD8− | +ve | +/+ | +ve | +ve |
E5 | Lymphoblastic | B220−, CD3+, CD4+, CD8− | +ve | +/+ | +ve | −ve |
H59 | Lymphoblastic | B220−, CD3+, CD4+, CD8− | +ve | +/+ | +ve | −ve |
E38 | Lymphoblastic | B220−, CD3+, CD4+, CD8− | +ve | +/+ | +ve | −ve |
J3 | Lymphoblastic | B220−, CD3+, CD4+, CD8− | +ve | −/+ | +ve | +ve |
E22 | Lymphoblastic | B220−, CD3+, CD4−, CD8+ | +ve | +/+ | +ve | −ve |
K1 | Lymphoblastic | B220−, CD3+, CD4−, CD8+ | +ve | +/+ | +ve | −ve |
F1-C3 | Lymphoblastic | B220−, CD3+, CD4−, CD8+ | +ve | −/+ | +ve | +ve |
Mouse . | Histology . | Immunophenotype . | TdT . | TCR Status β/δ . | RBTN-2 . | Tal-1 . |
---|---|---|---|---|---|---|
D8 | Lymphoblastic | B220−, CD3+, CD4−, CD8− | +ve | +/+ | +ve | +ve |
L12 | Lymphoblastic | B220−, CD3+, CD4−, CD8− | +ve | +/+ | +ve | +ve |
R15 | Lymphoblastic | B220−, CD3+, CD4−, CD8− | +ve | +/+ | +ve | −ve |
H27 | Lymphoblastic | B220−, CD3+, CD4−, CD8− | +ve | −/+ | +ve | −ve |
K7 | Lymphoblastic | B220−, CD3+, CD4−, CD8− | +ve | −/+ | +ve | −ve |
P21 | Lymphoblastic | B220−, CD3+, CD4+, CD8+ | +ve | +/+ | +ve | +ve |
T9 | Lymphoblastic | B220−, CD3+, CD4+, CD8+ | +ve | +/+ | +ve | +ve |
L15 | Lymphoblastic | B220−, CD3+, CD4+, CD8+ | +ve | +/+ | +ve | −ve |
F3 | Lymphoblastic | B220−, CD3+, CD4+, CD8+ | +ve | +/+ | +ve | −ve |
B20 | Lymphoblastic | B220−, CD3+, CD4+, CD8+ | +ve | +/+ | +ve | −ve |
S7 | Lymphoblastic | B220−, CD3+, CD4+, CD8+ | +ve | −/+ | +ve | −ve |
C31 | Lymphoblastic | B220−, CD3+, CD4+, CD8+ | +ve | −/+ | +ve | +ve |
F1-C2 | Lymphoblastic | B220−, CD3+, CD4+, CD8− | +ve | +/+ | +ve | +ve |
E5 | Lymphoblastic | B220−, CD3+, CD4+, CD8− | +ve | +/+ | +ve | −ve |
H59 | Lymphoblastic | B220−, CD3+, CD4+, CD8− | +ve | +/+ | +ve | −ve |
E38 | Lymphoblastic | B220−, CD3+, CD4+, CD8− | +ve | +/+ | +ve | −ve |
J3 | Lymphoblastic | B220−, CD3+, CD4+, CD8− | +ve | −/+ | +ve | +ve |
E22 | Lymphoblastic | B220−, CD3+, CD4−, CD8+ | +ve | +/+ | +ve | −ve |
K1 | Lymphoblastic | B220−, CD3+, CD4−, CD8+ | +ve | +/+ | +ve | −ve |
F1-C3 | Lymphoblastic | B220−, CD3+, CD4−, CD8+ | +ve | −/+ | +ve | +ve |
TdT refers to terminal deoxynucleotidyl transferase activity. TCR status refers to the T-cell receptor β and δ genes, and the (+) and (−) refers to the presence or absence of T-cell receptor gene rearrangements. For TCR δ the (+) includes both rearrangements and deletions.